ClinicalTrials.gg
Not yet recruitingNCT07019272Updated Jun 13, 2025

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

An observational study in HER2-positive Breast Cancer, sponsored by Hebei Medical University Fourth Hospital. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Hebei Medical University Fourth Hospital · Observational

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
170
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Breast Neoplasms by Hebei Medical University Fourth Hospital — 12 open to participants now, 14 under way, 1 of them phase 3. Breast Neoplasms · Hebei Medical University Fourth Hospital.

Started
2025
with 2 others
Observational
5 of 22
4 open now
Primary completion
2029-07
later than 13 of 13 live
Registered
16th of 22
by date

Among the 22 studies in Breast Neoplasms by Hebei Medical University Fourth Hospital, this one is one of 3 that started in 2025, is one of 5 observational ones, reaches primary completion later than 13 of the 13 other live ones, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 22 studies in Breast Neoplasms by Hebei Medical University Fourth Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Breast Neoplasms by Hebei Medical University Fourth Hospital, or all of them as a file.
02

Study summary

Neratinib is an oral, irreversible pan-HER tyrosine kinase inhibitor. Current treatment guidelines recommend neratinib as an extended adjuvant therapy for HER2-positive breast cancer patients to further reduce the risk of recurrence.

Even when HER2-positive breast cancer patients achieve pathological complete response (pCR) after neoadjuvant therapy, those with high-risk factors (such as large tumors [cT3/T4] or lymph node-positive disease) still face a risk of cancer returning. However, there is limited data on the effectiveness and safety of neratinib in these patients.

This study aims to provide real-world evidence on how well neratinib works in high-risk HER2-positive breast cancer patients who achieved pCR, helping to improve treatment strategies for Chinese patients.

Read the detailed description

This study is a single-arm prospective study with historical controls as external comparators

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

This study focuses on HER2-positive early breast cancer (EBC) patients who achieved pathological complete response (pCR) following neoadjuvant therapy but present with high-risk features (such as initial clinical stage cT3/T4 tumors or node-positive disease). These patients must have completed standard adjuvant therapy (including trastuzumab-based regimens) and initiated neratinib as extended adjuvant treatment within 6 months after completing their standard therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, female
  2. Clinical stage ≥cT3 or ≥cN1, regardless of hormone receptor (HR) status
  3. -positive: HER2 IHC 3+ or IHC 2+ with ISH+
  4. Achieved pathological complete response (pCR) after therapy
  5. Completed 1 year of standard adjuvant therapy (including trastuzumab), with ≤6 months between the last adjuvant treatment and starting neratinib
  6. No evidence of recurrence or disease (confirmed by clinical/imaging exams after completing standard adjuvant therapy and before starting neratinib)
  7. (LVEF) ≥50%
  8. performance status 0-1

Exclusion criteria

Exclusion Criteria:

  1. to any component of the drug
  2. Inability to swallow oral medication
  3. Participation in another interventional clinical trial within 4 weeks before enrollment, or planned participation during this study
  4. Use of any investigational drug within 14 days prior to treatment initiation
  5. Concurrent chemotherapy, radiotherapy, immunotherapy, or biologic therapy for breast cancer
  6. Severe psychiatric disorders preventing compliance with , treatment, or follow-up procedures
  7. Pregnancy, lactation, or plans for pregnancy in the near future
  8. Other significant medical conditions or laboratory abnormalities that, in the investigator's judgment, make participation unsuitable
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
170 participants (estimated)
Patient registry
No

Interventions

  • DrugNeratinibStudies of NeratinibNeratinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sequential neratinib extended adjuvant therapy will be initiated within 6 months after completing standard trastuzumab-based adjuvant therapy, continuing for 1 year. As a real-world non-interventional study, treating physicians will determine neratinib regimens per the prescribing information and current clinical practice. Neratinib Dosing: Standard regimen: 240 mg (6 tablets) once daily with food for 1 year; Dose escalation (to mitigate diarrhea, per latest CSCO Breast Cancer Guidelines and FDA labeling): Week 1: 120 mg/day (days 1-7) Week 2: 160 mg/day (days 8-14) Week 3 onward: 240 mg/day (days 15-365)

06

What researchers measure

Primary outcomes

  1. Invasive Disease Free Survival (IDFS)

    IDFS, as defined by the STEEP System, was measured from the date of treatment to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause.

    Time frame: From Day 1 of treatment until 2 years after treatment completion

Secondary outcomes

  1. Disease Free Survival (DFS)

    Disease-free survival is defined as the time from baseline until the first occurrence of DCIS or an iDFS event (an iDFS event including invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, or distant recurrence and death from any).

    Time frame: From Day 1 of treatment until 2 years after treatment completion

  2. Overall Survival (OS)

    OS was defined as the time from baseline to death due to any cause, censored at the last date known alive.

    Time frame: From Day 1 of treatment until 2 years after treatment completion

  3. Distant Disease-free Survival (DDFS)

    Distant disease-free survival time is defined as the time from baseline until the first occurrence of distant recurrence or death from any cause.

    Time frame: From Day 1 of treatment until 2 years after treatment completion

  4. Time to distant recurrence

    defined as time from baseline to the date of the first distant recurrence or death from breast cancer

    Time frame: From Day 1 of treatment until the first distant tumor recurrence or metastasis

  5. Cumulative incidence of CNS recurrence

    Time frame: From Day 1 of treatment until 2 years after treatment completion

  6. Incidence of grade ≥3 diarrhea

    Time frame: From consent to 28 days after last dose

  7. Incidence and severity of other adverse events (AEs)

    Time frame: From consent to 28 days after last dose

  8. Treatment patterns of patients

    Time frame: From Day 1 of treatment until last dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Jul 2029, 49 months later.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 49 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2025
First posted
Jun 13, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
Jul 31, 2029
CompletionEst.
Oct 31, 2030
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019272
Lead sponsor
Hebei Medical University Fourth Hospital
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Jun 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion